SABCS 2022 | 10-year results of a Phase III trial of low-dose tamoxifen in non-invasive breast cancer

Four years ago at the San Antonio Breast Cancer Symposium (SABCS), five-year data was presented on a Phase III TAM-01 (NCT01357772) trial exploring low-dose tamoxifen in invasive breast cancer and ductal carcinoma in situ (DCIS), demonstrating a 52% in recurrence versus placebo. Andrea De Censi, MD, PhD, National Hospital E.O. Ospedali Galliera – S.C. Oncologia Medica, Genoa, Italy, shares the 10-year result of TAM-01 presented at SABCS 2022, showing a 42% reduction of recurrence, with limited toxicity. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.